Envista (NYSE:NVST) Lowered to Buy Rating by Wall Street Zen

Envista (NYSE:NVST - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Saturday.

Several other analysts have also recently weighed in on NVST. Citigroup began coverage on shares of Envista in a research report on Wednesday, April 15th. They set a "neutral" rating and a $29.00 price objective on the stock. Leerink Partners set a $35.00 price objective on shares of Envista and gave the company an "outperform" rating in a research report on Friday, February 6th. Evercore reiterated an "outperform" rating and issued a $33.00 target price on shares of Envista in a research report on Thursday. William Blair upgraded shares of Envista from a "hold" rating to an "outperform" rating in a research report on Friday, February 6th. Finally, UBS Group lifted their target price on shares of Envista from $22.00 to $25.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 3rd. Six equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Envista presently has an average rating of "Hold" and an average price target of $28.83.

Envista Stock Performance

Envista stock opened at $24.27 on Friday. The firm's fifty day moving average price is $26.53 and its 200-day moving average price is $24.06. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.04 and a current ratio of 2.44. The stock has a market cap of $3.95 billion, a P/E ratio of 59.18, a price-to-earnings-growth ratio of 1.64 and a beta of 0.92. Envista has a fifty-two week low of $16.41 and a fifty-two week high of $30.42.

Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.05. The firm had revenue of $705.50 million for the quarter, compared to analysts' expectations of $680.04 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. The business's quarterly revenue was up 14.4% on a year-over-year basis. During the same quarter last year, the company posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, equities research analysts expect that Envista will post 1.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Mischa Reis sold 9,675 shares of Envista stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total value of $290,250.00. Following the transaction, the senior vice president owned 32,382 shares in the company, valued at $971,460. This trade represents a 23.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.99% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Envista

Large investors have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL bought a new stake in Envista during the third quarter worth about $1,664,000. ARGA Investment Management LP bought a new position in shares of Envista in the third quarter worth approximately $950,000. First Eagle Investment Management LLC bought a new position in shares of Envista in the third quarter worth approximately $4,329,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Envista by 22.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,149 shares of the company's stock worth $59,178,000 after buying an additional 523,949 shares in the last quarter. Finally, Jupiter Asset Management Ltd. lifted its stake in shares of Envista by 24.6% in the third quarter. Jupiter Asset Management Ltd. now owns 1,349,042 shares of the company's stock worth $27,480,000 after buying an additional 266,671 shares in the last quarter.

Key Headlines Impacting Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Envista reported better-than-expected Q1 2026 results, with EPS of $0.36 versus the $0.31 consensus and revenue of $705.5 million versus $680.0 million expected, suggesting solid demand and execution. Envista NYSE: NVST Posts Better-Than-Expected Sales In Q1 CY2026
• Positive Sentiment: Management’s earnings transcript and presentation are likely reinforcing confidence in the turnaround and highlighting new growth drivers, which can support the stock if investors see improving fundamentals. Envista (NVST) Q1 2026 Earnings Transcript
• Positive Sentiment: Robert W. Baird raised its price target on Envista to $31 from $30 and kept an outperform rating, while JPMorgan lifted its target to $29 from $26, signaling improved analyst sentiment after the earnings beat.
• Positive Sentiment: Zacks highlighted Envista as a top long-term growth stock, which may help reinforce the market’s view that the company has attractive longer-term earnings potential. Why Envista (NVST) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Additional coverage on the Q1 earnings snapshot and key metrics is mostly informational, but it keeps the company in focus as investors assess whether the earnings beat is sustainable. Envista: Q1 Earnings Snapshot
• Neutral Sentiment: The stock still faces some caution because JPMorgan’s rating remained neutral despite the higher target, indicating analysts see upside but not a clear near-term rerating.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company's offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista's product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.